艾司洛尔或兰地洛尔治疗脓毒症患者的死亡率:随机对照试验的系统评价与Meta分析及试验序列分析
该系统评价与Meta分析纳入8项RCT共885例脓毒症伴持续心动过速的成人患者,比较超短效β受体阻滞剂(艾司洛尔或兰地洛尔)与不用药或安慰剂对死亡率的影响。主要终点最長随访死亡率RR 0.84(95%CI 0.68-1.02,P=0.08,I²=51%),28天死亡率RR 0.77(95%CI 0.59-1.00,P=0.05,I²=62%),均未达统计学显著。亚组分析显示单中心与多中心RCT结果方向不同,试验序列分析提示两项死亡率结局均不稳健,敏感性分析显示加入非英语RCT后死亡率显著降低。作者认为现有证据不支持常规使用,需进一步研究。
要点
- 在脓毒症伴持续心动过速成人中,艾司洛尔或兰地洛尔未显著改善最長随访死亡率(RR 0.84,95%CI 0.68-1.02,P=0.08,I²=51%)。
- 28天死亡率也无显著改善(RR 0.77,95%CI 0.59-1.00,P=0.05,I²=62%)。
- 亚组分析提示单中心与多中心RCT的死亡率结果方向不同,试验序列分析显示两项死亡率结局均不稳健。
- 敏感性分析显示加入非英语RCT后死亡率显著降低,提示主要结局脆弱。
- 证据确定性极低,作者认为需进一步开展结合先进心脏监测或连续超声心动图的研究。
适用人群与场景
- 成人脓毒症伴持续心动过速患者,来自8项英文发表的RCT。
研究设计与关键结果
- 研究类型:系统评价与Meta分析(随机效应模型),纳入8项RCT共885例患者。
- 主要终点最長随访死亡率:RR 0.84(95%CI 0.68-1.02,P=0.08,I²=51%,证据确定性极低)。
- 28天死亡率:RR 0.77(95%CI 0.59-1.00,P=0.05,I²=62%)。
- 亚组分析显示单中心与多中心RCT的死亡率结果方向不同;试验序列分析显示两项死亡率结局均不稳健。
- 敏感性分析显示加入非英语RCT后死亡率显著降低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析(随机对照试验)。
- 证据等级:最長随访死亡率的证据确定性为极低。
- 局限:结果不稳健,单中心与多中心RCT结果方向不同,敏感性分析显示主要结局脆弱;需进一步研究。
对床旁实践的改变
- 作者认为,现有证据不支持艾司洛尔或兰地洛尔常规用于降低脓毒症伴持续心动过速患者的死亡率。
- 作者建议进一步开展结合先进心脏监测或连续超声心动图的研究。
指南或共识出处
- 国际前瞻性系统评价注册库(PROSPERO)注册号CRD42024503570。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The latest meta-analysis indicated potential survival benefits from ultra-short-acting β-blockers in patients with sepsis with persistent tachycardia. However, subsequent multicenter randomized controlled trials (RCTs) have reported conflicting findings, prompting the need for an updated meta-analysis to incorporate these newly published RCTs.
RESEARCH QUESTION: Does the use of ultra-short-acting β-blockers (esmolol or landiolol) in patients with sepsis with persistent tachycardia improve mortality?
STUDY DESIGN AND METHODS: We conducted an updated systematic search through April 2, 2024, exploring the MEDLINE, Cochrane Central Register of Controlled Trials, and Embase databases for RCTs reporting mortality in adult patients with sepsis treated with esmolol or landiolol as compared with those treated with neither of these or receiving placebo and published in English. Meta-analyses were conducted with the random effects model. The primary outcome was mortality at the longest follow-up, with subgroup analysis separating single-center RCTS from large multicenter RCTs.
RESULTS: Eight RCTs (885 patients) were included in the primary analysis. Ultra-short-acting β-blockers did not improve mortality significantly at the longest follow-up (risk ratio, 0.84; 95% CI, 0.68-1.02; P = .08; I2 = 51%; very low certainty of the evidence) and 28-day mortality (risk ratio, 0.77; 95% CI, 0.59-1.00; P = .05; I2 = 62%). Subgroup analyses of mortality outcomes pointed toward different results between single-center and multicenter RCTs. Trial sequence analyses showed that both mortality outcomes were not robust. The sensitivity analyses suggested a significant reduction in mortality by adding RCTs published in non-English languages.
INTERPRETATION: In this updated meta-analysis, the use of esmolol or landiolol did not reduce mortality in patients with sepsis with persistent tachycardia. However, results were not robust and outcomes differed between single-center and multicenter RCTs. Moreover, sensitivity analyses showed the fragility of the primary outcome. Further studies regarding ultra-short-acting β-blockers with advanced cardiac monitoring or serial echocardiography are warranted.
TRIAL REGISTRY: International Prospective Register of Systematic Reviews; No.: CRD42024503570; URL: https://www.crd.york.ac.uk/prospero/.
参考来源
- Sato R, Messina S, Hasegawa D, et al. Mortality in Patients With Sepsis Treated With Esmolol or Landiolol: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With Trial Sequential Analysis. Chest. 2024. PMID: 39197514. doi:10.1016/j.chest.2024.08.020
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。